Daraxonrasib Gets FDA Approval for Pancreas Cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines received a certain FDA approval for its drug daraxonrasib for metastatic pancreatic cancer patients with tumor progression after chemotherapy.
- daraxonrasib will become the new standard of care in the second‑line setting once the FDA clears it, pending the speed of the company’s submission.
- ASCO gave daraxonrasib a standing ovation during its plenary session, highlighting the drug’s impact.
- Revolution Medicines is exploring expansion of daraxonrasib to newly diagnosed metastatic pancreatic cancer patients, according to post‑ASCO discussions.
Why it matters: Patients with metastatic pancreatic cancer will receive a faster second‑line therapy, while rivals lose market share as daraxonrasib becomes the new standard of care after rapid FDA clearance.
